Get the Stockscreener App
9.61
3.71%
-0.37
Forte Biosciences Inc stock is traded at $9.61, with a volume of 35,772.
It is down -3.71% in the last 24 hours and down -22.75% over the past month.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
See More
Previous Close:
$9.98
Open:
$10.22
24h Volume:
35,772
Relative Volume:
0.40
Market Cap:
$63.27M
Revenue:
-
Net Income/Loss:
$-31.48M
P/E Ratio:
-9.2404
EPS:
-1.04
Net Cash Flow:
$-28.71M
1W Performance:
-17.16%
1M Performance:
-22.75%
6M Performance:
-39.52%
1Y Performance:
-29.98%
1-Day Range:
$9.46
$10.32
1-Week Range:
$9.46
$12.03
52-Week Range:
$4.11
$28.68
Forte Biosciences Inc Stock (FBRX) Company Profile
Name
Forte Biosciences Inc
Sector
Industry
Phone
(310) 618-6994
Address
3060 PEGASUS PARK DRIVE, DALLAS, CA
Compare FBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
9.61 | 121.89M | 0 | -31.48M | -28.71M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-21-25 | Initiated | TD Cowen | Buy |
| Apr-08-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Sep-20-21 | Upgrade | Chardan Capital Markets | Sell → Buy |
| Sep-03-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Sep-03-21 | Downgrade | Chardan Capital Markets | Buy → Sell |
| Sep-03-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-03-21 | Downgrade | Truist | Buy → Hold |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Mar-26-21 | Initiated | Citigroup | Buy |
| Aug-28-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-25-20 | Initiated | Truist | Buy |
View All
Forte Biosciences Inc Stock (FBRX) Latest News
What makes Forte Biosciences Inc. stock price move sharplySecure Trading Strategy Based on Technical Analysis - Newser
What MACD and RSI say about Forte Biosciences Inc.Free Quick Gain Stock Watch With Indicators - Newser
Multi factor analysis applied to Forte Biosciences Inc.Free Wealth Building Stock Market Ideas - Newser
Does Forte Biosciences Inc. stock perform well during market downturnsSmart Portfolio Planner For Beginners - jammulinksnews.com
Combining price and volume data for Forte Biosciences Inc.Technical Chart Summary for Momentum Stocks - Newser
How to build a custom watchlist for Forte Biosciences Inc.Chart Scanner for Swing Trade Timing - Newser
Real time alert setup for Forte Biosciences Inc. performanceOversold Reversal Picks with Buy Zone - Newser
When is Forte Biosciences Inc. stock expected to show significant growthBeginner Investor Guidance For 2025 - jammulinksnews.com
Should I hold or sell Forte Biosciences Inc. stock in 2025Chart Pattern Opportunities With High Returns - jammulinksnews.com
Identifying reversal signals in Forte Biosciences Inc.Buy Point Strategy with Profit Protection - Newser
What MACD signals say about Forte Biosciences Inc.AI Volatility Forecast and Risk Monitor - Newser
How Forte Biosciences Inc. stock performs during market volatilityIntelligent Trade Forecast With AI Analytics - Newser
Forte Biosciences Inc. Company’s Quarterly Earnings Growth: What the Numbers SayFree Trend Following Strategy With Stop Loss - Newser
How Resilient Is Forte Biosciences Inc. Stock During Economic DownturnsWeekly Top Gainers Forecast Watchlist Released - metal.it
How Interest Rate Changes Impact Forte Biosciences Inc. Stock PerformanceConservative Equity Setup with Signal Analysis - Newser
Price Channel Expanding on Forte Biosciences Inc.’s ChartWeekly Stock Opportunity Radar Scanner Activated - metal.it
Will Forte Biosciences Inc. Sustain Its Chart BreakoutSmart Allocation Stock Pick Insights Gaining Interest - metal.it
What is Forte Biosciences Inc. company’s growth strategyExplosive earnings growth - jammulinksnews.com
What are the latest earnings results for Forte Biosciences Inc.Discover hidden gems in the stock market - jammulinksnews.com
Is Forte Biosciences Inc. stock overvalued or undervaluedCapitalize on fast-growing investment opportunities - jammulinksnews.com
What catalysts could drive Forte Biosciences Inc. stock higher in 2025Smart Portfolio Alerts That Work - jammulinksnews.com
What is the risk reward ratio of investing in Forte Biosciences Inc. stockMaximize portfolio returns with smart trading - jammulinksnews.com
What are Forte Biosciences Inc. company’s key revenue driversGame-changing capital returns - jammulinksnews.com
How does Forte Biosciences Inc. compare to its industry peersUnlock powerful insights from market experts - jammulinksnews.com
What drives Forte Biosciences Inc. stock priceSkyrocketing returns - PrintWeekIndia
Will Forte Biosciences Inc. stock split in the near futureRapid wealth multiplication - jammulinksnews.com
Is Forte Biosciences Inc. a good long term investmentRapid-fire capital growth - Autocar Professional
Forte Biosciences Sees Unusually High Options Volume (NASDAQ:FBRX) - Defense World
What analysts say about Forte Biosciences Inc. stockSky-high return potential - Autocar Professional
Forte Biosciences Inc. Stock Analysis and ForecastFree Wealth Planning Blueprint - jammulinksnews.com
Forte Biosciences Inc Stock (FBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Forte Biosciences Inc Stock (FBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wagner Paul A. | SEE REMARKS |
Jul 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
81,038 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Apr 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,372 |
| Wagner Paul A. | SEE REMARKS |
Apr 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
79,806 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jan 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,151 |
| Wagner Paul A. | SEE REMARKS |
Jan 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
78,720 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Nov 21 '24 |
Buy |
5.55 |
22,514 |
124,998 |
30,776 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Oct 01 '24 |
Option Exercise |
0.00 |
375 |
0 |
8,395 |
| Wagner Paul A. | SEE REMARKS |
Oct 01 '24 |
Option Exercise |
0.00 |
1,250 |
0 |
77,568 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):